Search Results

Press Releases

ProKidney to Participate in the UBS Virtual Organ Restoration Day

October 9, 2024

·

1 min read

Press Releases

ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference

November 6, 2024

·

1 min read

Bio NC

ProKidney to Participate in the 2024 Jefferies Global Healthcare Conference

ProKidney Corp. announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from June 4 – 6, 2024 in New York, NY.

May 29, 2024

·

1 min read

Press Releases

ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024

October 14, 2024

·

2 min read

Bio NC

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

ProKidney Corp. announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses.

June 10, 2024

·

5 min read

Drug Development

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

ProKidney Corp. announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company’s renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical and operational updates.

June 10, 2024

·

7 min read

Business

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

March 21, 2024

·

14 min read

Bio NC

ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that it has closed its SEC-registered underwritten public offering and concurrent registered direct offering.

June 17, 2024

·

4 min read

Bio NC

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

ProKidney Corp. announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions.

June 11, 2024

·

5 min read

Press Releases

ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

·

1 min read